Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) and PainReform (NASDAQ:PRFX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.
Risk and Volatility
Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its share price is 196,142% less volatile than the S&P 500. Comparatively, PainReform has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
Profitability
This table compares Eloxx Pharmaceuticals and PainReform’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
| PainReform | N/A | N/A | N/A |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eloxx Pharmaceuticals | $6.36 million | 9.64 | -$5.99 million | ($1.54) | -9.86 |
| PainReform | $31,000.00 | 24.07 | -$5.02 million | ($736.66) | -0.00 |
PainReform has lower revenue, but higher earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Eloxx Pharmaceuticals and PainReform, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eloxx Pharmaceuticals | 1 | 0 | 2 | 2 | 3.00 |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
Eloxx Pharmaceuticals currently has a consensus price target of $38.33, suggesting a potential upside of 152.53%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Eloxx Pharmaceuticals is more favorable than PainReform.
Institutional & Insider Ownership
2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
